Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCR pseudogene 3 (BCRP3) is a long noncoding RNA (lncRNA), not a protein-coding gene, derived from sequences homologous to the BCR (breakpoint cluster region) gene. BCRP3 is part of a family of BCR-related pseudogenes, but unlike BCR, it functions at the RNA level rather than encoding a protein. BCRP3 is cytoplasmic and acts as a positive regulator of autophagy: it binds to and activates the VPS34 kinase complex, thereby stimulating the process of aggrephagy, which selectively removes ubiquitinated protein aggregates. This function plays a role in protein quality control and cellular stress responses, supporting cell survival under proteotoxic conditions such as oxidative stress or proteasome inhibition. While BCRP3's mechanistic importance in autophagy is becoming clearer, it is not known to be a therapeutic target or a biomarker and does not currently have links to approved drugs or clinical indications[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCR pseudogene 3 (BCRP3).